What Scienture Holdings does

Scienture Holdings, Inc. (NASDAQ: SCNX) is a Delaware-incorporated specialty pharmaceutical holding company headquartered in Commack, New York, operating through its wholly owned subsidiary Scienture, LLC. The company develops, licenses, and commercializes branded prescription pharmaceutical products in the US market. Its current commercial portfolio consists of two FDA-approved products: REZENOPY (naloxone HCl nasal spray, 10mg), an opioid overdose reversal agent licensed exclusively for US commercialization from Kindeva Drug Delivery and Summit Biosciences in March 2025; and Arbli (losartan potassium oral suspension), an antihypertensive approved by the FDA in March 2025. REZENOPY began commercial shipments to US wholesalers in July 2026, entering a US naloxone market that the company characterizes at approximately $144 million annually and 9.8 million units.

The company's revenue model is built on branded prescription pharmaceutical sales through US wholesale distribution, supported by Group Purchasing Organization (GPO) agreements covering 5,000+ healthcare institutions (~60% of the US institutional market) and payer access covering 100M+ covered lives. Beyond its two approved products, Scienture is developing a pipeline of candidates targeting migraine, thrombosis, and postoperative pain indications, indicating a product-line expansion strategy within specialty therapeutics. The business model relies on regulatory exclusivity from FDA approvals, exclusive licensing arrangements with development partners, and broad institutional channel access to drive prescription volume.

Name

Scienture Holdings

Legal name

Scienture Holdings, Inc.

Website

https://scientureholdings.com

Company type

Public

Operating status

Operating

Short description

Scienture Holdings is a specialty pharmaceutical holding company that develops and commercializes branded prescription products including REZENOPY (naloxone nasal spray) and Arbli (losartan oral suspension), serving US healthcare institutions and patient populations through wholesale and GPO distribution channels.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Specialty pharmaceuticals
• Naloxone nasal spray
• Cardiovascular therapeutics
• Opioid overdose treatment
• Pharmaceutical distribution

Headquarters

HQ city

Commack

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of FDA-approved specialty pharmaceutical products including REZENOPY (naloxone HCl nasal spray) and Arbli (losartan potassium oral suspension) to healthcare institutions and through pharmaceutical wholesalers.
2. Licensing and Commercialization Rights: Exclusive commercial license agreements for proprietary pharmaceutical products, such as the agreement with Kindeva Drug Delivery for REZENOPY and Summit Biosciences for commercialization rights.

Go-to-market motion2 records

Distribution channels2 records

Core offering

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that develops, commercializes, and distributes novel specialty drug products through its wholly-owned subsidiary Scienture, LLC. Its commercial portfolio includes REZENOPY (naloxone HCl nasal spray 10mg), the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension) for cardiovascular treatment. The company also maintains a clinical-stage development pipeline focused on cardiovascular and central nervous system diseases.

Product overview

Scienture Holdings, Inc. is a specialty pharmaceutical holding company that operates through its subsidiary Scienture, LLC. The company is focused on developing and commercializing novel specialty products for cardiovascular and central nervous system diseases. Its FDA-approved product portfolio includes REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg, the highest-dose FDA-approved naloxone nasal spray in the U.S., and Arbli (losartan potassium oral suspension). The company also maintains a clinical-stage development pipeline with candidates for migraine, thrombosis, and postoperative pain treatment. The company has secured payer access covering more than 100 million covered lives and has established GPO agreements providing access to over 5,000 healthcare institutions.

Differentiator

Problem solved

Functional benefit

Brands

• Scienture, LLC: New York-based pharmaceutical company developing unique specialty products that bring enhanced value to patients and healthcare systems.

Products and services

• REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg The highest-dose FDA-approved naloxone hydrochloride nasal spray available in the U.S. market, addressing the approximately $144 million annual U.S. naloxone market for opioid overdose reversal. Sold to U.S. pharmaceutical wholesalers and through GPO agreements to healthcare institutions.
• Arbli (losartan potassium oral suspension) FDA-approved oral suspension formulation of losartan potassium for cardiovascular treatment, received approval through subsidiary Scienture LLC. Provides a liquid dosage option for patients requiring antihypertensive therapy.

Quantifiable outcome

• REZENOPY targets the $144 million annual U.S. naloxone market
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Kindeva Drug DeliverycoreOEM/ Whitelabel/ Licensing Partner · 1 March 2025Exclusive commercial license agreement for REZENOPY (naloxone HCl nasal spray 10mg) signed in March 2025. Kindeva Drug Delivery provides manufacturing and commercialization rights for the highest-dose FDA-approved naloxone nasal spray.
• Summit Biosciences Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 March 2025Exclusive U.S. commercialization rights agreement for REZENOPY naloxone nasal spray secured in March 2025. This partnership enabled the company to access payer coverage and institutional markets.

Scale indicators5 records

Recent moves7 records

Expansion highlights3 records

Broad incumbents

• ANI Pharmaceuticals: Specialty and generic pharmaceutical company with a diversified portfolio across multiple therapeutic areas. Comparable as a small/mid-cap specialty pharma with a similar institutional GPO/wholesaler distribution model.
• Endo International: Specialty and generic pharmaceutical company with established CNS, pain, and cardiovascular franchises. Comparable as a specialty pharma with overlapping therapeutic areas including pain and cardiovascular.
• Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management and CNS therapeutics. Comparable given the overlap in CNS therapeutic focus and specialty pharma commercial model.
• Supernus Pharmaceuticals: Specialty pharmaceutical company focused on CNS products, particularly in neurology and psychiatry. Comparable given the CNS therapeutic focus that overlaps with Scienture's migraine and pain pipeline.
• Assertio Holdings: Specialty pharmaceutical company with branded neurology, inflammation, and pain products. Comparable in scale and therapeutic focus on specialty CNS/pain markets where Scienture's pipeline operates.
• Hikma Pharmaceuticals: Global specialty and generic pharmaceutical company with a strong U.S. institutional presence, including injectable and nasal spray products. Comparable business model targeting institutional buyers and wholesalers.
• Teva Pharmaceutical Industries: Global pharmaceutical manufacturer producing generic naloxone and other specialty/generic products. Comparable as a competitor in the naloxone market and as a broader specialty/generic pharma peer.

Direct peers

• Indivior: Specialty pharmaceutical company focused on opioid use disorder and substance-use treatment. Compares to Scienture given shared focus on the opioid-related therapeutic space and institutional channel distribution.
• Emergent BioSolutions: Maker of Narcan, the dominant FDA-approved naloxone nasal spray and the primary direct competitor to REZENOPY. Emergent is the incumbent leader in the U.S. opioid overdose reversal market that Scienture is targeting.
• Amphastar Pharmaceuticals: Specialty pharmaceutical manufacturer with a portfolio that includes naloxone injectable products and other hospital-focused injectables. Directly comparable given the institutional/specialty pharma business model and naloxone presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scienture Holdings